Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer's Disease
The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) and vascular dementia (VaD) are intertwined by mixed dementia (MD) harboring varying degrees of AD pathology in combination with cerebrovascular disease. The aim was to assess whether there is a difference in the cerebrospinal fluid (CSF) profile, of selected proteins, between patients with VaD and MD with subcortical vascular disease (SVD), AD, and healthy controls that could contribute in the separation of the groups. The study included 30 controls, 26 SVD patients (9 VaD and 17 MD) and 30 AD patients. The protein panel included total tau (T-tau), hyperphosphorylated tau 181 (P-tau(181)), amyloid β 1-42 (Aβ(1-42)), neurofilament light (NF-L), myelin basic protein (MBP), heart fatty acid binding protein (H-FABP), matrix metalloproteinases (MMP-1, -2, -3, -9, and -10), and tissue inhibitors of metalloproteinases (TIMP-1 and -2). Immunochemical methods were utilized for quantification of the proteins in CSF and data analysis was performed with a multivariate discriminant algorithm. The concentrations of MBP, TIMP-1, P-tau(181), NF-L, T-tau, MMP-9, Aβ(1-42), and MMP-2 contributed the most to the separation between SVD and AD, with a sensitivity of 89% and a specificity of 90% (AUC = 0.92). MBP and NF-L performed the best in discriminating SVD from controls, while T-tau and Aβ(1-42) contributed the most in segregating AD from controls. The CSF biomarkers reflecting AD pathology (T-tau, P-tau(181), and Aβ(1-42)), white matter lesions (NF-L and MBP) and ma…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while increased levels of metaloproteinases MMP-1, MMP-3 and MMP-10 have also been reported in AD [223,224,225,226].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [224]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease
Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S., & Perry, G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02653.1997 · Cited by 1,239 · cited 1×
“There are many detailed studies supporting these findings [68–75].”
Barrett, A. J., & Starkey, P. M. (1973) · Biochemical Journal · doi:10.1042/bj1330709 · Cited by 1,062 · cited 1×
“Further complicating the picture is the regulation of the MMPs by TIMPs and that the inhibitors have a biological function of their own [10, 11, 13, 14].”
Metalloproteinases in biology and pathology of the nervous system
Yong, V. W., Power, C., Forsyth, P., & Edwards, D. R. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081571 · Cited by 1,060 · cited 3×
“Mounting evidence indicates that matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) may play an important role in the pathology of neurodegenerative and neuroinflammatory diseases [10–12].”
Tibbling, G., Link, H., & Ohman, S. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517709091496 · Cited by 966
Rosenberg, G. A., Estrada, E. Y., & Dencoff, J. E. (1998) · Stroke · doi:10.1161/01.str.29.10.2189 · Cited by 861
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationHeterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations
Gouw, A. A., Seewann, A., van der Flier, W. M., Barkhof, F., Rozemuller, A. M., Scheltens, P., & Geurts, J. J. G. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.204685 · Cited by 766
Progress in matrix metalloproteinase research
MURPHY, G., & NAGASE, H. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.05.002 · Cited by 759 · cited 2×
“structural proteins such as tight junction proteins and MBP [11, 58, 59].”
Multi- and megavariate data analysis
Eriksson, L. (2006) · Cited by 736
Cited by
Items 101–184 of 184
Small Vessel Disease: Ancient Description, Novel Biomarkers
Moretti, R., & Caruso, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073508 · Cited by 26
Brown, R. B., Traylor, M., Burgess, S., Sawcer, S. J., & Markus, H. S. (2019) · Stroke · doi:10.1161/strokeaha.118.023649 · Cited by 26
“3 Proinflammatory enzymes are elevated in the cerebrospinal fluid of patients with vascular cognitive impairment 4 and blood biomarkers of inflammation, including IL (interleukin)-6 and CRP (C-reactive protein), have been associated with the presence of WMHs. 5 Plasma levels of inflammatory…”
Cerebrospinal fluid biomarkers of β‐amyloid metabolism and neuronal damage in epileptic seizures
Shahim, P., Ręjdak, R., Książek, P., Blennow, K., Zetterberg, H., Mattsson, N., & Rejdak, K. (2013) · European Journal of Neurology · doi:10.1111/ene.12336 · Cited by 27
“Previous studies have found correlations between H-FABP and T-tau/P-tau [22].”
ResultSelf-citationRosa-Neto, P., Hsiung, G.-Y., Masellis, M., & participants, O. B. O. T. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt223 · Cited by 23
“A few studies found that CSF neurofilament elevation is associated with the presence of white matter changes, whereas CSF neurofilament is normal in AD [90-92].”
BackgroundBrosseron, F., Kleemann, K. L., Kolbe, C., Santarelli, F., Castro‐Gomez, S., Tacik, P. M., Latz, E., Jessen, F., & Heneka, M. T. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15175 · Cited by 24
“Its increased CSF levels are interpreted as early markers of neuronal damage (Bjerke et al., 2011, 2016; Chiasserini et al., 2017; Harari et al., 2014; Höglund et al., 2017; Matsui et al., 2010; Olsson et al., 2013, 2016; Steinacker et al., 2004).”
BackgroundMethodGanguly, K., Adhikary, K., Acharjee, A., Acharjee, P., Trigun, S. K., Mutlaq, A. S., Ashique, S., Yasmin, S., Alshahrani, A. M., & Ansari, M. Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135967 · Cited by 26
Bjerke, M., Kern, S., Blennow, K., Zetterberg, H., Wærn, M., Börjesson‐Hanson, A., Östling, S., Kern, J., & Skoog, I. G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150525 · Cited by 23
“The criteria for VaD were similar to the criteria proposed by the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherce et l´Enseignement en Neurosciences (NINDS-AIREN) [32].”
BackgroundResultInfluentialSelf-citationHessen, E., Nordlund, A., Stålhammar, J., Eckerström, M., Bjerke, M., Eckerström, C., Göthlin, M., Fladby, T., Reinvang, I., & Wallin, A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150109 · Cited by 23
“Conversely, clear associations between T-tau and vascular dementia have not been found [47] and the fairly homogeneous subtype subcortical vascular dementia does not exhibit deviations of T-tau [48].”
BackgroundSelf-citationPanda, S. P., & Soni, U. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101560 · Cited by 22
Plasma MMP-9/TIMP-1 ratio serves as a novel potential biomarker in Alzheimer’s disease
Liu, J., Li, X., & Qu, J. (2023) · Neuroreport · doi:10.1097/wnr.0000000000001952 · Cited by 22
Metalloproteinases and neurodegenerative diseases: pathophysiological and therapeutic perspectives
Rosenberg, G. A. (2015) · Metalloproteinases In Medicine · doi:10.2147/mnm.s68849 · Cited by 27
Idland, A., Sala‐Llonch, R., Watne, L. O., Brækhus, A., Hansson, O., Blennow, K., Zetterberg, H., Sørensen, Ø., Walhovd, K. B., Wyller, T. B., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.04.002 · Cited by 23
“Positive correlations of FABP3 with YKL-40 and NFL have, however, previously been reported in populations including patients (Bjerke et al., 2011; Harari et al., 2014).”
BackgroundSelf-citationJeppsson, A., Bjerke, M., Hellström, P., Blennow, K., Zetterberg, H., Kettunen, P., Wikkelsø, C., Wallin, A., & Tullberg, M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.839307 · Cited by 23
“Here, increased CSF levels of MMP-9 and TIMP1 (at trend level), together with increased NFL and MBP, are in agreement with earlier suggestions of what characterizes a subcortical CSF profile and with earlier findings in patients with SSVD (42).”
BackgroundResultSelf-citationThe cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
Mäkitalo, S., Mellgren, Å., Borgh, E., Kilander, L., Skillbäck, T. B., Zetterberg, H., & Gisslén, M. (2015) · AIDS Research and Therapy · doi:10.1186/s12981-015-0063-x · Cited by 22
“In AD, NFL may be moderately elevated [29, 32], particularly in older patients where a mixed pathology of other diseases, such as vascular dementia, may be present [19] and patients with late onset AD who may demonstrate white matter pathology on radiological investigation [33].”
BackgroundSelf-citationSystemic and Disease-Specific Risk Factors in Vascular Dementia: Diagnosis and Prevention
Jaul, E., & Meiron, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00333 · Cited by 24
“Some researchers proposed the abnormal expression of myelin basic protein (MBP) to be the endophenotype for development of VaD but further validation studies were needed before definite proof of this concept (Bjerke et al., 2011; Meiron et al., 2017).”
BackgroundSex-specific associations of matrix metalloproteinases in Alzheimer’s disease
Aksnes, M., Edwin, T. H., Saltvedt, I. T., Eldholm, R. S., Chaudhry, F. A., Halaas, N. B., Myrstad, M., Watne, L. O., & Knapskog, A. (2023) · Biology of Sex Differences · doi:10.1186/s13293-023-00514-x · Cited by 21
Aβ1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases
Nutu, M., Bourgeois, P., Zetterberg, H., Portelius, E., Andréasson, U., Parent, S., Lipari, F., Hall, S., Constantinescu, R., Hansson, O., et al. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8208-8 · Cited by 22
Self-citationYan, T., Yu, J., Zhang, Y., & Li, T. (2015) · Europe PMC (PubMed Central) · Cited by 19
Matrix metalloproteinases are associated with brain atrophy in cognitively unimpaired individuals
Aksnes, M., Capogna, E., Dídac Vidal-piñeiro, A., Chaudhry, F. A., Myrstad, M., Idland, A., Halaas, N. B., Dakhil, S., Blennow, K., Zetterberg, H., et al. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.05.012 · Cited by 18
Self-citationChai, Y. L., Rajeev, V., Poh, L., Selvaraji, S., Hilal, S., Chen, C., Jo, D., Koo, E. H., Arumugam, T. V., & Lai, M. K. P. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221146401 · Cited by 19
Dai, S. J., Zhang, J. Y., Bao, Y. T., Zhou, X. J., Lin, L. N., Fu, Y. B., Zhang, Y. J., Li, C., & Yang, Y. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.07.020 · Cited by 18
Kamalian, A., Ho, S. G., Patel, M. A., Lewis, A., Bakker, A., Albert, M., O’Brien, R., Moghekar, A., & Lutz, M. W. (2023) · Biomolecules · doi:10.3390/biom13071094 · Cited by 18
Early Detection and Treatment of Patients with Alzheimer’s Disease: Future Perspectives
Guest, F. L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-05542-4_15 · Cited by 19
Hosoki, S., & Sachdev, P. S. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01938 · Cited by 16
“…that a biomarker panel encompassing proteins, such as neurofilament light chain and matrix metalloproteinase-9, combined with tau protein and Aβ 42 exhibited a high degree of accuracy in differentiating patients with AD from those with subcortical ischemic vascular dementia (Bjerke et al., 2011).”
BackgroundAltered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer’s Disease
Park, J., Cho, S., Jo, C., Park, M. H., Han, C., Kim, E., Huh, G. Y., & Koh, Y. H. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050827 · Cited by 15
Serum Brevican as a Biomarker of Cerebrovascular Disease in an Elderly Cognitively Impaired Cohort
Chia, R. S. L., Minta, K., Wu, L., Salai, K. H. T., Chai, Y. L., Hilal, S., Venketasubramanian, N., Chen, C., Chong, J. R., & Lai, M. K. P. (2024) · Biomolecules · doi:10.3390/biom14010075 · Cited by 15
“Since TIMPs are known to be inhibitors of MMPs and ADAMTS and are associated with VaD [49,50], it would be of interest to assess the potential roles of TIMPs and other ECM components in cerebrovascular disease pathogenesis.”
BackgroundCerebrospinal fluid in the dementias
Zetterberg, H., Rohrer, J. D., & Schott, J. M. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804279-3.00006-x · Cited by 17
Self-citationJohansson, L. H., Sacuiu, S. F., Kern, S., Guo, X., Zetterberg, H., Blennow, K., Zettergren, A., & Skoog, I. G. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.013 · Cited by 14
“Psychological stress in midlife was also associated with higher levels of CSF MBP, a sign of myelin disintegration that may lead to neuronal damage (Bjerke et al., 2011).”
BackgroundSelf-citationSachdev, P. S. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000577 · Cited by 13
Selecting Aβ Isoforms for An Alzheimer’s Disease Cerebrospinal Fluid Biomarker Panel
Somers, C., Goossens, J., Engelborghs, S., & Bjerke, M. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0276 · Cited by 13
Self-citationSasaki, Y., Kimura, N., Aso, Y., Yabuuchi, K., Aikawa, M., & Matsubara, E. (2021) · Biomolecules · doi:10.3390/biom11101496 · Cited by 12
Machado, G. F., de Melo, G. D., Souza, M. S., Machado, A. A., Migliolo, D. S., Moraes, O. C., Nunes, C. M., & Ribeiro, É. S. (2013) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2013.04.006 · Cited by 12
“Further, MMPs and TIMPs, together with other classical biomarkers, have been used to differentiate Alzheimer’s disease from vascular dementia (Bjerke et al., 2011), but biomarkers do not usually have relevance in clinical animal diagnosis and prognosis.”
Michopoulou, S. K., Prosser, A. M. J., Kipps, C., Dickson, J. C., Guy, M., & Teeling, J. L. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220523 · Cited by 11
New candidate blood biomarkers potentially associated with white matter hyperintensities progression
Jiménez-Baladó, J., Pizarro, J., Llena, I. R., Peñalba, A., Faura, J., Palà, E., Montaner, J., Hernández‐Guillamón, M., & Delgado, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-93498-w · Cited by 12
CSF YKL‐40 and GAP‐43 are related to suicidal ideation in older women
Rymo, I., Kern, S., Bjerke, M., Zetterberg, H., Marlow, T., Blennow, K., Gudmundsson, P., Skoog, I. G., & Wærn, M. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12701 · Cited by 13
“MPB is found in oligodendrocytes and myelin sheets and plays an important role in neuroinflammatory processes leading to neuronal damage (15).”
BackgroundSelf-citationKettunen, P., Bjerke, M., Eckerström, C., Jonsson, M. A. G., Zetterberg, H., Blennow, K., Svensson, J., & Wallin, A. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12296 · Cited by 12
“CSF concentrations of Aβ1-42, the axonal damage marker t-tau, and p-tau181 were measured using sandwich enzymelinked immunosorbent assays (ELISAs; INNOTEST β-AMYLOID (1-42), INNOTEST hTAU Ag, and INNOTEST PHOSPHO-TAU (181P), respectively; Fujirebio, Gent, Belgium).”
MethodSelf-citationBlood-brain barrier at the interface of air pollution-associated neurotoxicity and neuroinflammation
Young, T. L., Zychowski, K. E., Denson, J. L., & Campen, M. J. (2018) · Advances in neurotoxicology · doi:10.1016/bs.ant.2018.10.010 · Cited by 18
Kimura, N., Aikawa, M., Etou, K., Aso, Y., & Matsubara, E. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200810171322 · Cited by 10
Rosenberg, G. A., Prestopnik, J., Knoefel, J. E., Adair, J. C., Thompson, J., Raja, R., & Caprihan, A. (2019) · Brain Sciences · doi:10.3390/brainsci9080187 · Cited by 12
“Others have observed elevated MMP-10 in AD, but the significance of this observation is unclear [26].”
BackgroundMoyano, P. M., Vicente-Zurdo, D., Blázquez-Barbadillo, C., Menéndez, J. C., González, J. F., Rosales‐Conrado, N., & del Pino, J. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00333 · Cited by 10
Sarkar, S., Gharami, K., Mondal, A., Padmanabhan, K., Paidi, R. K., Srikumar, B. N., & Biswas, S. C. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02060-6 · Cited by 9
“…[10] and can be correlated to the concentration of TIMP-1 detected in the CSF of healthy individuals (human adults) ranging from 60 ng/ml to 160 ng/ml [24] calculated with respect to the average CSF volume in mice (around 40 µl) where the intracerebroventricularly injected TIMP-1 gets distributed.”
Brutto, V. J. D., Khasiyev, F., Omran, S. S., Purohit, M., Liu, M., Wright, C. B., Rundek, T., Elkind, M. S. V., Sacco, R. L., & Gutierrez, J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318819 · Cited by 9
Do, A. N., Song, S., Ali, M., Timsina, J., Wang, L., Western, D., Liu, M., Sanford, J., Rosende-Roca, M., Boada, M., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71063 · Cited by 8
Duchateau, L., Küҫükali, F., Roeck, A. D., Wittens, M. M. J., Temmerman, J., Weets, I., Timmers, M., Engelborghs, S., Bjerke, M., & Sleegers, K. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01338-y · Cited by 8
“In addition, we selected chitinase-3-like protein 1 (CHI3L1; also known as YKL-40) to investigate a role of ABCA7 in glial activation and neuroinflammation and heart fatty acid binding protein (hFABP) which further reflects neurode-generation [13, 16, 18, 19].”
BackgroundSelf-citationOcenasova, A., Shawkatová, I., Javor, J., Párnická, Z., Minárik, G., Kralova, M., Kiralyova, I., Mikolášková, I., & Ďurmanová, V. (2023) · Life · doi:10.3390/life13040882 · Cited by 8
“According to previous studies, MMP-2 has been proposed as one of the CSF biomarkers related to the detection of AD patients [25,26].”
MethodMoyano, P. M., Vicente-Zurdo, D., Blázquez-Barbadillo, C., Menéndez, J. C., González, J. F., Rosales‐Conrado, N., & del Pino, J. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113264 · Cited by 7
Andrén, E. A., Kettunen, P., Bjerke, M., Rolstad, S., Zetterberg, H., Blennow, K., Wallin, A., & Svensson, J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230680 · Cited by 6
Self-citationUnderstanding the Intricate Role of Exosomes in Pathogenesis of Alzheimer’s Disease
Chauhan, S., Behl, T., Sehgal, A., Singh, S., Sharma, N., Gupta, S., Albratty, M., Najmi, A., Meraya, A. M., & Alhazmi, H. A. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00621-4 · Cited by 6
“Recently, CSF p-tau and CSF A1-42 combinations has been widely researched as diagnostic biomarker capable of discriminating AD from other neurodegenerative diseases in initial stages (Bjerke et al. 2011).”
BackgroundHoyer-Kimura, C. H., & Hay, M. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115815 · Cited by 5
Alvarado, A. J. M., Brito, C. C., Román, G. C., Gareri, P., Aguilar-Navarro, S. G., Sandoval, J. L. R., Calleja-Castillo, J. M., Velázquez, C., Ardila, G. P., Merino, M. S. C., et al. (2017) · Journal of Neurology and Neuroscience · doi:10.21767/2171-6625.1000224 · Cited by 6
Alzheimer’s Disease Cerebrospinal Fluid (CSF) Biomarkers
Khan, T. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00005-5 · Cited by 5
Genetic susceptibility to vascular cognitive impairment: a pathophysiological view
Manso-Calderón, R., & González‐Sarmiento, R. (2016) · Future Neurology · doi:10.2217/fnl-2016-0002 · Cited by 4
An astrocyte-derived cytokine TIMP-1 restores synaptic plasticity in an Alzheimer’s disease modelPreprint
Sarkar, S., Gharami, K., Paidi, R. K., Srikumar, B. N., & Biswas, S. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.18.533245 · Cited by 4
Добрынина, Л. А., Tsypushtanova, M. M., Шабалина, А. А., Витальевна, Ш. К., Геннадьевна, М. А., Trubitsyna, V. V., Bitsieva, E. T., Byrochkina, A. A., & Geints, A. A. (2023) · Annals of Clinical and Experimental Neurology · doi:10.54101/acen.2023.3.3 · Cited by 3
“ний при ЦМА продемонстрирована корреляция повышен-ного уровня NEFL в ЦСЖ с тяжестью ГИБВ и атрофией на МРТ головного мозга [35, 43, 44].”
Potential Protective Effect of Dl-3-n-butylphthalide on Chronic Cerebral Ischemia Brain Injury
Zhao, F., & Luo, Y. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666211221160922 · Cited by 3
Liu, M., Hu, H., Fu, Y., Chi, H., Huang, L.-Y., Tan, L., & Hu, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05442-y · Cited by 2
“…study have previously been confirmed to be associated with cognitive decline or AD, including well-established proteins such as neurofilament light polypeptide (NEFL) [29, 30], as well as more recently recognized proteins in dementia research, including 14–3-3 proteins and MMP10 [6, 19, 31, 32].”
Cerebrospinal fluid biomarkers for neurodegenerative disorders
Videira, R. M. A. S. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 3
Blood-Brain Barrier Permeability and Inflammation in Cerebral Small Vessel Disease
Walsh, J. (2019) · Apollo (University of Cambridge) · doi:10.17863/cam.50869 · Cited by 2
Multifaceted Role of Matrix Metalloproteases on Human Diseases
Roy, S., Pramanik, A., Chakraborti, T., & Chakraborti, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-3162-5_2 · Cited by 2
“[26] suggested that MMP-9 and TIMP-1 could be used as biomarkers of AD in addition to T-tau, P-tau, Ab1–42, and white matter lesions.”
BackgroundPan, L., Ou, Y., Tan, L., Tan, L., & Yu, J. (2021) · Brain Science Advances · doi:10.26599/bsa.2021.9050003 · Cited by 1
Windon, C., & Elahi, F. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-49963-0_30 · Cited by 1
Alzheimer's disease-associated biomarkers in delirium and cognitively normal older adults
Idland, A. (2020) · NVA (Nasjonalt vitenarkiv) · Cited by 2
Cerebrospinal fluid biomarkers for differentiating between Alzheimer’s disease and Vascular dementia
Bjerke, M. (2011) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Self-citationNeuroimaging and laboratory aspects
Pantoni, L., & Gorelick, P. B. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139382694.012
Cerebral small vessel disease: cerebrospinal fluid aspects
Wallin, A., & Bjerke, M. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139382694.018
Self-citationOikonomou, P. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6174
Use of cerebrospinal fluid in diagnosis of dementia
Nuti, A., Carlesi, C., Ienco, E. C., Cipriani, G., & Dotto, P. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00014-8
MMP-9 and TIMP-1 Levels in Children and Adolescents with Obsessive Compulsive Disorder
Dalyan, S., Çoban, Ö. G., Erdem, B. K., Yolcu, Ö., Önder, A., Adanır, A. S., Nasıroğlu, S., & Akbaş, S. H. (2023) · Neurochemical Journal · doi:10.1134/s1819712423010038
Lindemann, H. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9889
Immune dysregulation and neurodegenerative diseases
Cipollini, V., Troili, F., & Giubilei, F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85841-0.00015-8
Duchateau, L., Küҫükali, F., Roeck, A. D., Wittens, M. M. J., Temmerman, J., Weets, I., Timmers, M., Engelborghs, S., Bjerke, M., & Sleegers, K. (2023) · Figshare · doi:10.6084/m9.figshare.24540665
Self-citationFatty acid-binding proteins and brain diseases
Duttaroy, A. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95700-7.00011-5
Deciphering the molecular and neuropathological dimensions of dementia
Dutta, S., Bhattacharjee, P., Noori, S., Adhikari, N., Dule, S., Soyel, M. I., Besra, M., Borah, S., & Gupta, P. (2025) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/j.npg.2025.05.002
Duchateau, L., Küҫükali, F., Roeck, A. D., Wittens, M. M. J., Temmerman, J., Weets, I., Timmers, M., Engelborghs, S., Bjerke, M., & Sleegers, K. (2024) · Figshare · doi:10.6084/m9.figshare.24540868
Self-citationAdditional file 1 of Sex-specific associations of matrix metalloproteinases in Alzheimer’s disease
Aksnes, M., Edwin, T. H., Saltvedt, I. T., Eldholm, R. S., Chaudhry, F. A., Halaas, N. B., Myrstad, M., Watne, L. O., & Knapskog, A.-B. (2023) · Figshare · doi:10.6084/m9.figshare.23118925
Molecular mechanisms of action of MT-MMPs involved in the pathogenesis of Alzheimer’s disease
García‐González, L. (2020) · theses.fr (ABES) · doi:10.70675/a04672c0z1f4az472ezbcd5zbea446eac50c
Valverde, A. (2020) · theses.fr (ABES) · doi:10.70675/f1b70734zf4e3z4870z8fbdz950d831642a7
Song, W., Liu, X., Yu, T., Xiang, Y., Fu, P., Wu, M., Yin, X., Zhang, X., & Chen, Z. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71667
Frank, M., Barthélémy, C., Dufour, A., Rivera, S., & Baranger, K. (2026) · The Enzymes · doi:10.1016/bs.enz.2026.07.004
Matrix Metalloproteinases as an Inflammatory Mediator in the Neurovascular Unit
Xing, C., Maki, T., Seo, J. H., Arai, K., & Lo, E. H. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8915-3_6
Metadata
- Authors
- Bjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U.
- Affiliations
- University of Gothenburg (SE)
- Institute of Neuroscience and physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
- Corresponding author
- Bjerke, Maria
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2011-11-29
- Volume
- 27
- Issue
- 3
- Pages
- 665-676
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1585099387
- Cited by
- 180
- References
- 78
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 10 · 2023: 18 · 2022: 14 · 2021: 16 · 2020: 17 · 2019: 12 · 2018: 12 · 2017: 14 · 2016: 10 · 2015: 19 · 2014: 13 · 2013: 11 · 2012: 3
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- vascular dementia, Alzheimer's disease
- MeSH terms
- Aged, Alzheimer Disease, Cerebral Cortex, Myelin Basic Protein, Female, Humans, Male, Middle Aged, Phosphorylation, Dementia, Vascular, Biomarkers, tau Proteins, Neurofilament Proteins, Tissue Inhibitor of Metalloproteinase-1, Matrix Metalloproteinase 9
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.